发明名称 COMBINATION THERAPY
摘要 A pharmaceutical combination comprising (a) a compound of formula (I),;;or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering.
申请公布号 US2016287605(A1) 申请公布日期 2016.10.06
申请号 US201615184399 申请日期 2016.06.16
申请人 Sheng Qing;Wang Hui-Qin;Li Fang;Liang Jinsheng;Cao Zhu Alexander;Monahan John;Versace Richard 发明人 Sheng Qing;Wang Hui-Qin;Li Fang;Liang Jinsheng;Cao Zhu Alexander;Monahan John;Versace Richard
分类号 A61K31/5377;A61K31/506 主分类号 A61K31/5377
代理机构 代理人
主权项 1. A pharmaceutical combination comprising: (a) compound having Formula:and (b) 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or pharmaceutically acceptable salt thereof.
地址 Sharon MA US